B
iopharmaceutical-based therapy of ischemic heart disease, especially gene therapy and stem-cell therapy, shows promising results in animal and clinical studies. 1 Vascular endothelial growth factor (VEGF), an angiogenic cytokine, plays an important role in these therapies [2] [3] [4] through VEGF-induced migration of stem cells to ischemic myocardium and neovascularization (including angiogenesis and arteriogenesis). [5] [6] [7] However, studies show that VEGF might exert protective functions that extend far beyond its angiogenic activity and stem cell-mediated cardiac repair activity. 8, 9 Protecting cardiomyocytes from apoptosis and imposing a positive inotropic effect on cardiomyocytes demonstrate that VEGF might have direct effects on cardiomyocytes, which may also contribute to its cardioprotection ability. 10, 11 VEGF activates phosphatidylinositol 3-kinase (PI3K) through binding to the VEGF type-2 receptor and produces multitudinous functions. 12, 13 PI3K-mediated signaling has proved to be involved in the regulation of ion channels and cardiac action potential (AP) and plays an important role in antiarrhythmia. [14] [15] [16] The delayed rectifier potassium current (I K ) is the major outward current responsible for AP repolarization. Two components of the I K , a slowly activating delayed rectifier potassium current (I Ks ) and a rapidly activating delayed rectifier potassium current (I Kr ), have been identified in many mammalian species. Dysfunction of I K is related to a change in action potential duration (APD) and may contribute to the creation of arrhythmia.
Therefore, we hypothesized that VEGF exerts direct effects on I K and other cardiac electrical properties, which are poorly understood. We investigated the effects of VEGF on I K and AP parameters in guinea pig ventricular myocytes to explore the therapeutic potential and safety profiles of VEGF in arrhythmia and other cardiovascular diseases.
Methods
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data that support the findings of this study are available from the corresponding author on reasonable request.
Myocytes Isolation
Animal protocols used in this study were approved by the Institutional Animal Care and Use Committee of Zhengzhou University for Medical Research. Single ventricular myocytes were obtained from adult guinea pigs (female, 250-350 g). Ventricular myocytes obtained from the first guinea pig were used for I Ks and I Kr recording; ventricular myocytes obtained from the second guinea pig were used for AP recording; ventricular myocytes obtained from the third guinea pig were used to investigate whether PI3K-mediated signaling is related to VEGF-induced effects. There were no repeated measurements on the same experimental unit. The isolation procedure is similar to the previously described method. 18, 19 The heart excised from a guinea pig was initially placed on a Langendorff apparatus and perfused with Ca 2+ -free Tyrode The I Ks current traces were elicited in response to voltage steps from À40 to +60 mV in 10-mV increments with a duration of 5 seconds, followed by a repolarized potential of À40 mV to test the tail current. The membrane potential was held at À40 mV. To record I Ks , E4031 (2 lmol/L) was added to the extracellular solution to block I Kr . The I Kr current traces were elicited in response to the voltage steps from À60 to +60 mV in 10-mV increments with a duration of 4 seconds, followed by a repolarized potential of À60 mV to test the tail current. The membrane potential was held at À60 mV. To record I Kr , chromanol 293B (30 lmol/L) was added to the extracellular solution to block I Ks .
Clinical Perspective
What Is New?
• Because the mechanisms of vascular endothelial growth factor (VEGF) on electrical properties of cardiomyocytes have not been fully elucidated, we investigated the direct effects of VEGF on delayed rectifier potassium current and action potential parameters.
• VEGF inhibited the slowly activating delayed rectifier potassium current in a concentration-dependent manner through a phosphatidylinositol 3-kinase-mediated signaling pathway, leading to action potential duration prolongation.
• VEGF had no significant effect on the rapidly activating delayed rectifier potassium current, resting membrane potential, action potential amplitude, or maximal velocity of depolarization.
What Are the Clinical Implications?
• The results show that stabilizing cardiac electrical activity may be 1 of the cardioprotective properties of VEGF and indicate a promising therapeutic potential of VEGF in prevention of ventricular tachyarrhythmias under conditions of high sympathetic activity and ischemia.
Single Myocyte AP Recording
APs were recorded in the whole-cell, single-electrode, currentclamp configuration. The extracellular solution was composed of (in mmol/L) NaCl 140, KCl 3.5, HEPES 10, D-glucose 10, NaH 2 PO 4 1.25, MgCl 2 1, CaCl 2 2; pH was adjusted to 7.4 with NaOH. The pipette was filled with a solution composed of the following (in mmol/L): K-gluconate 140 mmol/L, NaCl 5, MgCl 2 1, CaCl 2 0.1, Mg-ATP 2, HEPES 10, EGTA 1; pH was adjusted to 7.2 with KOH. APs were recorded in response to a 10-ms current, which was determined by a leading current step from 0 to 900 pA in 100-pA increments with a duration of 10 ms.
Drug Application
Recombinant VEGF165 proteins (Sino Biological Inc, Beijing, China) of different concentrations (10, 40, 100, and 300 ng/ mL) were included in the medium for 10 minutes during the with or without 10, 40, 100, and 300 ng/mL VEGF. Current traces were elicited in response to voltage steps from À60 to +60 mV in 10-mV increments with a duration of 4 seconds; holding potential was À60 mV. Chromanol 293B was added to isolate I Kr . B, The current-voltage curves of the I Kr -tail recorded in controls and in the presence of different concentrations of VEGF. C, Summarized data of I Kr -tail current density at +40 mV. I Kr indicates rapidly activating delayed rectifier potassium current; NS, not significant; VEGF, vascular endothelial growth factor.
dose-response experiments. In some experiments isolated ventricular cardiomyocytes were pretreated with a PI3K inhibitor (100 nmol/L wortmannin, Selleck Chemicals, Houston, TX) for 1 hour before the addition of VEGF165 (100 ng/ mL), and the inhibitor was present throughout the experiments in order to determine whether PI3K-mediated signaling is involved in VEGF165-induced inhibition of I Ks and prolongation of APD.
Statistical Analysis
The data were presented as meanAESEM and analyzed with SPSS 19.0 (SPSS Inc, Chicago, IL). Student t test or a 1-way ANOVA followed by Bonferroni analysis for multiple comparisons were used to determine the statistical significance. A value of P<0.05 was considered statistically significant.
Results

Effects of VEGF on I Ks
We initially tested the effects of different concentrations of VEGF on I Ks . Isolated guinea pig ventricular myocytes were treated with 10, 40, 100, and 300 ng/mL VEGF ( Figure 1A) . At +60 mV, the summarized data (n=5) of I Ks current density (pA/pF) was 18.13AE1.04 (control), 16.42AE0.57 (10 ng/mL), 12.73AE0.34 (40 ng/mL), 10.19AE0.50 (100 ng/mL), 9.05AE1.20 (300 ng/mL) ( Figure 1B ). At 10 ng/mL, VEGF treatment did not have significant effects on I Ks compared with control group (P>0.05). There was also no significant difference between the 100 and 300 ng/mL VEGF treatment groups (P>0.05). Figures 1C and 1D show the current-voltage curves of the I Ks and I Ks -tail under the control condition and using different concentrations of VEGF. I Ks was significantly inhibited in a concentration-dependent manner. The currentvoltage relationship was not affected.
Effects of VEGF on I Kr
We also tested the effects of VEGF on I Kr . Within the voltage range of À60 to +60 mV, a comparison of VEGF treatment groups with different concentrations showed no significant differences when compared with the control group, and no significant difference was observed between these VEGF treatment groups. In addition, the current-voltage relationship was not affected (Figures 2A and 2B) . At +40 mV, the summarized data (n=5) of I Kr -tail current density (pA/pF) was 1.02AE0.06 (control), 0.99AE0.08 (10 ng/mL), 1.10AE0.07 (40 ng/mL), 0.81AE0.10 (100 ng/mL), and 1.07AE0.07 (300 ng/mL) ( Figure 2C ).
Effects of VEGF on the Activation of I Ks and I Kr
Compared with the control group, the 300 ng/mL VEGF treatment group did not show an altered voltage-dependent activation of the I Ks and I Kr channels. The half-maximally activated potentials (V 1/2 ) of I Ks and I Kr were not affected significantly ( Figures 3A and 3B ).
Effects of Wortmannin on VEGF-Induced I Ks Inhibition
We used wortmannin, a PI3K inhibitor, to study whether PI3K mediated signaling is related to VEGF-induced I Ks inhibition. Figure 4A shows the representative recordings of I Ks in isolated guinea pig ventricular myocytes treated with the control condition, 100 ng/mL VEGF and 100 ng/mL VEGF plus wortmannin (100 nmol/L). Figures 4C and 4D show the current-voltage curves of I Ks and I Ks -tail for the control group, 100 ng/mL VEGF group, and 100 ng/mL VEGF plus wortmannin group. There was no significant difference in the amplitudes of I Ks between the control and those recorded in the presence of 100 ng/mL VEGF plus wortmannin. Wortmannin eliminated the VEGF-induced I Ks inhibition.
Effects of VEGF on AP Parameters
To investigate the effects of VEGF on the cell membrane potential, isolated guinea pig ventricular myocytes were treated with 100 ng/mL VEGF. Figure 5A shows the AP waveforms of the 100 ng/mL VEGF treatment group and the control group. Recordings of I Ks obtained from samples treated with the control condition, 100 ng/mL VEGF and 100 ng/mL VEGF plus wortmannin. B, Summarized data of I Ks current density at +60 mV. *P<0.05, NS indicates not significant. C, The current-voltage curves of I Ks for the control group, 100 ng/mL VEGF group and 100 ng/mL VEGF plus wortmannin group. D, The current-voltage curves of the I Ks -tail for the control group, 100 ng/mL VEGF group and 100 ng/mL VEGF plus wortmannin group. I Ks indicates slowly activating delayed rectifier potassium current; NS, not significant; VEGF, vascular endothelial growth factor.
APD at 50% repolarization (APD50) and 90% repolarization (APD90) were prolonged Figures 5B through 5E ). Figure 5F shows the APD for the control group, the 100 ng/mL VEGF group, and the 100 ng/mL VEGF plus wortmannin group. Wortmannin eliminated the VEGF-induced prolongation of APD50 (100 ng/mL VEGF group versus 100 ng/mL VEGF plus wortmannin group: 805.8AE38.04 ms versus 678.1AE39.75 ms, respectively; n=5, P=0.028) and APD90 (100 ng/mL VEGF group versus 100 ng/ mL VEGF plus wortmannin group: 894.5AE36.92 ms versus 749.1AE32.02 ms, respectively; n=5, P=0.020).
Discussion
The key observations of the present study are as follows. First, VEGF inhibited I Ks in a concentration-dependent manner in guinea pig ventricular myocytes. I Ks was not further inhibited by 300 ng/mL VEGF, probably indicating that the VEGF cell membrane receptors were saturated by 100 ng/mL VEGF ( Figure 1C ). Second, VEGF at different concentrations did not have a significant effect on I Kr . Third, VEGF did not alter the activation of I Ks and I Kr . Fourth, VEGF prolonged APD50 and APD90 at the concentration of 100 ng/mL but had no effect on other AP parameters. Fifth, a PI3K inhibitor eliminated VEGF-induced inhibition of I Ks and APD prolongation, suggesting that VEGF induced its effects mainly in a PI3K signaling-dependent mechanism.
AP repolarization is an important phenomenon in cardiac myocytes. I K , composed of I Kr and I Ks , acts as a major outward current during repolarization, blockage of which leads to delayed repolarization and the prolongation of APD. I Ks is the major outward current during the period of plateau repolarization. 20 Therefore, VEGF-induced APD prolongation may partially be attributed to inhibition of I Ks . In addition, the L-type calcium current, an inward current during the plateau phase of repolarization, also affects the APD. Our previous studies have found that VEGF increased L-type calcium current in guinea pig ventricular myocytes. 21 Therefore, VEGF-induced enhancement of L-type calcium current may also be 1 of the mechanisms underlying VEGF-induced APD prolongation. Most class III antiarrhythmic drugs are highly selective I Kr channel blockers and lengthen APD in a reverse frequencydependent manner. 22, 23 These drugs have little APD-prolonging effect under the condition of a high heart rate, limiting their therapeutic potency against tachyarrhythmias. In addition, APD Figure 5 . Effect of 100 ng/mL VEGF on action potential parameters in single cardiac ventricular myocytes (per group; sample size: n=5).
A, Recordings of action potential in the control and in the presence of 100 ng/mL VEGF in isolated guinea pig ventricular myocytes. B through E, Summary of the effects of 100 ng/mL on APD (B), APA (C), Max (dv/dt) (D), and RMP (E). F, Summarized data of APD for the control group, 100 ng/mL VEGF group and 100 ng/mL VEGF plus wortmannin group. With regard to the treatment of ischemic heart disease, especially myocardial infarction, VEGF has shown great potential for cardioprotection, including attenuating infarct size, preventing ventricular remodeling and improving cardiac function. 3, 4, 31 In addition, it should be noted that VEGF genebased therapy for ischemic heart disease has been shown to avoid serious or lethal arrhythmias. 8 This finding suggests that stabilizing cardiac electrical activity is also an important part of VEGF-induced cardioprotection. It is known that sympathetic overactivity is closely associated with the incidence of malignant arrhythmias, 32, 33 in which increasing I Ks may be involved. Therefore, inhibition of I Ks probably is the underlying mechanism in prevention of malignant ventricular arrhythmias. However, because I Ks blockage contributes to long-QT syndrome, 34 more extensive studies are needed to investigate the safety profiles of VEGF in the treatment of arrhythmia and ischemic heart disease. This future research will help predict the direct clinical outcome of I Ks inhibition by VEGF. It is known that the I Ks channel is composed of a subunits and function-altering b subunits, and the I Kr channel is composed of HERG and unestablished b subunits. 17 Studies
show that the b subunit of I Ks plays an essential role in acute I Ks inhibition, in which PI3K-mediated signaling is involved. 35 This finding may explain why VEGF inhibited I Ks but had no effect on I Kr .
